Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Financials
Key financial figures for Recursion Pharmaceuticals, Inc. Class A Common Stock (Q2 2026).
Recursion Pharmaceuticals, Inc. reported revenue of $7.7 million for Q2 FY2026, down 59.8% from the same period a year earlier. The company posted a net loss of $131.0 million, or -$0.25 per share. Operating margin came to -1759.69%, against -922.51% a year earlier. Free cash flow for the period was -$107.9 million. Across the last 5 reported quarters, quarterly revenue has moved from $19.1 million in Q2 FY2025 to $7.7 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Recursion Pharmaceuticals, Inc. are on the SentiSense financials page.
- Revenue
- $8M
- Net Income
- -$131M
- EPS
- $-0.25
- Total Assets
- $1.2B
- Operating Cash Flow
- -$106M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $8M | -$131M | -$0.25 | -1759.69% | -$108M |
| Q1 FY2026 | $6M | -$118M | -$0.22 | -1985.55% | -$81M |
| Q4 FY2025 | $36M | -$108M | -$0.21 | -304.84% | -$47M |
| Q3 FY2025 | $5M | -$162M | -$0.36 | -3327.57% | -$118M |
| Q2 FY2025 | $19M | -$172M | -$0.41 | -922.51% | -$80M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $75M | -$645M | -$1.44 | -867.87% | -$378M |
| FY2024 | $59M | -$464M | -$1.69 | -814.09% | -$373M |
| FY2023 | $44M | -$328M | -$1.58 | -797.84% | -$300M |
Frequently asked questions
What was Recursion Pharmaceuticals, Inc.'s revenue last quarter?
Recursion Pharmaceuticals, Inc. reported revenue of $7.7 million for Q2 FY2026, down 59.8% from the same period a year earlier.
Is Recursion Pharmaceuticals, Inc. profitable?
Not in its most recent reported period. Recursion Pharmaceuticals, Inc. reported a net loss of $131.0 million for Q2 FY2026, a net margin of -1708.02% on revenue.
How has Recursion Pharmaceuticals, Inc.'s margin trended?
Operating margin was -1759.69% in Q2 FY2026, compared with -922.51% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Recursion Pharmaceuticals, Inc. generate?
Recursion Pharmaceuticals, Inc. generated free cash flow of -$107.9 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Recursion Pharmaceuticals, Inc. Class A Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.